Teragen Bio Launches Disease Prediction Personal Genetic Testing Service 'HelloGene 4.0'

Possessing the Largest Number of 141 Test Items Domestically

Teragen Bio.

[Asia Economy Reporter Lee Gwan-joo] Theragen Bio announced on the 13th that it has launched the disease prediction personal genetic testing service 'Hellozin 4.0'. This upgrade is the first change in five years since the release of the 'Hellozin 3.0' version in 2017, which supplemented Korean genetic markers.

The disease prediction personal genetic testing service 'Hellozin 4.0' features a gene analysis algorithm based on a Korean database, selecting and conducting meaningful genes repeatedly reported in research groups of various ethnicities. It also improved disease prediction accuracy by using three or more multi-markers per disease.

In 'Hellozin 4.0', the number of markers and genes verified in Koreans and Asians nearly doubled, and the number of test items increased by about 69% from 97 to 141 compared to the previous version. It added 12 types of cancer and 33 types of common diseases, for which gene analysis result reporting is actively conducted, and for the first time in Korea, customized items related to mental health, matching recent healthcare trends.

Theragen Bio holds the largest number of test items in the industry with 141 types across disease prediction standards by domestic genetic testing companies, including cancer, common diseases, drug response, and rare diseases. So far, it has provided personal genetic testing through more than 700 medical institutions nationwide.

This content was produced with the assistance of AI translation services.